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Background: Alcohol use disorders (AUDs) lead to alterations in central nervous system (CNS) architecture along
with impaired learning and memory. Previous work from our group and that of others suggests that one
mechanism underlying these changes is alteration of cell proliferation, apoptosis, and DNA-repair in neural stem
cells (NSCs) produced as a consequence of ethanol-induced effects on the expression of genes related to
p53-signaling. This study tests the hypothesis that changes in the expression of p53-signaling genes represent
biomarkers of ethanol abuse which can be identified in the peripheral blood of rat drinking models and human
AUD subjects and posits that specific changes may be correlated with differences in neuropsychological measures
and CNS structure.
Results: Remarkably, microarray analysis of 350 genes related to p53-signaling in peripheral blood leukocytes (PBLs)
of binge-drinking rats revealed 190 genes that were significantly altered after correcting for multiple testing.
Moreover, 40 of these genes overlapped with those that we had previously observed to be changed in
ethanol-exposed mouse NSCs. Expression changes in nine of these genes were tested for independent
confirmation by a custom QuantiGene Plex (QGP) assay for a subset of p53-signaling genes, where a consistent
trend for decreased expression of mitosis-related genes was observed. One mitosis-related gene (Pttg1) was also
changed in human lymphoblasts cultured with ethanol. In PBLs of human AUD subjects seven p53-signaling genes
were changed compared with non-drinking controls. Correlation and principal components analysis were then
used to identify significant relationships between the expression of these seven genes and a set of medical,
demographic, neuropsychological and neuroimaging measures that distinguished AUD and control subjects. Two
genes (Ercc1 and Mcm5) showed a highly significant correlation with AUD-induced decreases in the volume of the
left parietal supramarginal gyrus and neuropsychological measures.
Conclusions: These results demonstrate that alcohol-induced changes in genes related to proliferation, apoptosis,
and DNA-repair are observable in the peripheral blood and may serve as a useful biomarker for CNS structural
damage and functional performance deficits in human AUD subjects.
Keywords: Biomarker, Peripheral blood, Microarray, p53, DNA damage, Alcoholism, Neuroimaging* Correspondence: middletf@upstate.edu
1Departments of Neuroscience & Physiology, Upstate Medical University, 750
East Adams Street, Syracuse, NY 13210, USA
2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA
Full list of author information is available at the end of the article
© 2012 Hicks et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hicks et al. BMC Neuroscience 2012, 13:128 Page 2 of 13
http://www.biomedcentral.com/1471-2202/13/128Background
Alcohol use disorders (AUDs), which encompass both
alcohol addiction and dependence, cause significant
structural and functional deficits in the adult human
brain. Adult alcoholics display neuronal loss in the
hippocampus and superior frontal association cortex
[1,2] along with increased ventricle size and sulcal
widening [3]. Cognitive deficits often accompany these
changes and are characterized by impaired anterograde
spatial memory [4] and episodic learning [5]. Yet, the
predominant clinical tests used to identify pathology in
AUD subjects focus on molecular changes within the
liver [6,7].
Alcohol exposure also causes molecular changes
within the central nervous system (CNS). For example,
long-term exposure to alcohol has been associated with
changes in gene expression related to neurogenesis, neu-
roprotection and neurodegeneration within the frontal
cortex [8,9], cell cycle and neuronal differentiation
within the superior frontal cortex [10], and DNA-repair
and apoptosis within the nucleus accumbens and pre-
frontal cortex [11]. Moreover, some of the reproducible
expression changes in these classes of genes were found
to reliably predict AUD status [9]. Despite these compel-
ling results based on post-mortem human tissue, there
are numerous limitations to such studies that reduce
their potential utility for biomarker discovery in AUDs,
including CNS tissue availability, agonal state, post-
mortem interval, brain pH and other variables.
Studying alterations in gene expression levels in per-
ipheral blood offers an intriguing alternative to brain-
based biomarkers. It is believed that 80% of genes
expressed in brain tissue are expressed in blood, and the
subtle changes in the brain associated with injury or dis-
ease may be reflected by changes in gene expression in
blood [12]. The common origin of microglial cells and
white blood cells from bone marrow-derived monocytes
allow them to share the expression of many surface
receptors and signaling proteins related to the immune
response [13]. It has been posited that peripheral lym-
phocytes recruited through the blood brain barrier in re-
sponse to brain injury may be exposed to previously
hidden antigens, which could lead to clonal expansion
and differentiation of lymphocytes as well as changes in
circulating lymphocyte gene expression profiles [14]. In
support of this, studies have demonstrated overlap in the
expression of Alzheimer’s-related genes in the blood and
brain suggesting the potential for particular genes in per-
ipheral blood cells to function as biomarkers for diagno-
sis and prognosis and also as targets for therapy of CNS
disease and injury [13].
Previously we have demonstrated that the exposure of
cultured NS-5 neural stem cells (NSCs) to alcohol
results in significant changes in the expression of genesrelated to cell proliferation, DNA repair, and apoptosis –
functions related to p53 signaling [15,16]. The present
study proposes to examine whether changes in these
pathways are reliably and robustly observed in the per-
ipheral blood of animal drinking models and human
AUD subjects. Because NSCs and peripheral leukocytes
are both highly proliferative cell populations, we
hypothesize that alcohol-induced changes in p53 signal-
ing genes will be similar in these cell types. Furthermore,
we hypothesize that some of the consistent changes in
human AUD subjects will be correlated with structural
and functional measures of CNS function as well as their
alcohol use severity.
Methods
Mouse neural stem cells
An overview of the experimental design and workflow is
provided in Additional file 1 figure S1. The present study
specifically examined human and rat PBLs for changes
in expression of genes related to p53 signaling, cell pro-
liferation, apoptosis and DNA repair. This derived from
our previously published microarray-based examination
of changes in mouse NSCs exposed to ethanol in vitro
[15], where robust expression alterations in these path-
ways were observed and confirmed using both real-time
quantitative RT-PCR and immunocytofluorescent stain-
ing. The original microarray data set on the mouse
NSCs is available for download in the NCBI Gene Ex-
pression Omnibus (GSE 19436). Because the methods
have also been described in detail [15,16], they are only
summarized here. Briefly, a line of non-immortalized,
pluripotent NS-5 NSCs was derived from embryonic
mouse brains at day 11.5 of gestation. Approximately
100,000 cells were plated (in an 8 ml volume) in
100 mm petri dishes coated with poly-L-ornithine
hydrobromide (15 ug/ml; Sigma) and laminin (10 ug/ml;
Sigma). Cultures were maintained in supplemented
Euromed-N medium until they reached 30% confluency
and then exposed for 48 hours to either FGF2 or TGFβ1
(10 ng/ml) or ethanol (400 mg/dL) and a growth factor
in Euromed Media (Peprotech). Three petri dishes were
used for each condition and placed inside airtight con-
tainers with 400 mg/dL ethanol or sterile water to main-
tain the ethanol concentration of the media. Total RNA
was purified from each sample and used for either
microarray analysis using the GeneChip Mouse 430 2.0
Array (Affymetrix) or real-time quantitative RT-PCR
using the RT2 First-Strand Kit and PCR arrays (SA
Biosciences).
Rat studies
A total of 20 (10 male and 10 female) Long-Evans rats
obtained from Harlan Labs were used for these studies.
Animals were cared for in accordance with protocols
Table 1 Ethanol-induced gene expression changes in
human lymphoblasts
Gene Log2 Change T test P Mann–Whitney P
TP73 -0.24 0.0076 0.0495
HUS1 -0.33 0.0186 0.0495
GADD45A -0.38 0.0272 0.0495
ATM -0.30 0.0525 0.0495
CASP3 -0.31 0.0725 0.1266
PTTG1 -0.11 0.0764 0.0495
CCND1 -0.44 0.1024 0.1266
CDK1 -0.37 0.1143 0.1266
CDC25C -0.29 0.1196 0.1266
MUTYH -0.25 0.1658 0.0495
ERCC1 -0.19 0.1724 0.1266
CD40 -0.46 0.1801 0.0495
CCNB2 -0.12 0.2423 0.5127
ATR -0.23 0.2561 0.1266
CHEK1 -0.17 0.2595 0.1266
CDK4 0.09 0.3009 0.5127
E2F3 -0.34 0.3205 0.2752
CCNA2 -0.35 0.3559 0.5127
CASP8 -0.20 0.3597 0.2752
PCNA -0.26 0.3729 0.5127
APEX1 0.09 0.3942 0.2752
PARP1 0.10 0.4639 0.2752
JUN -0.22 0.5296 0.5127
XRCC5 0.05 0.5766 0.5127
FADD -0.09 0.5912 0.5127
FASLG -0.37 0.6082 0.8273
TNFRSF10B 0.06 0.6242 0.5127
RACGAP1 -0.15 0.6435 0.8273
APAF1 -0.08 0.8085 0.8273
MDM4 -0.06 0.8190 0.5127
TP53 -0.07 0.8410 0.8273
HPRT1 0.00 0.8822 0.5127
PPIA 0.00 0.8917 0.5127
BCL2 0.03 0.8928 0.8273
MCM5 -0.02 0.9212 0.5127
MYC 0.02 0.9242 0.8273
These genes represent the complete set of genes analyzed by QuantiGene
Plex 2.0. assays in cultured human lymphoblasts as well as primary human and
rat PBLs.
Nominally significant observations are indicated in boldface italics.
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(CHUA) at SUNY Upstate Medical University. These
animals were housed in individual cages and exposed to
a 12 hour reverse light/dark cycle. Fresh food was pro-
vided to all rats at 10:00 AM. At postnatal day 29 rats
were split into four groups (two treatment and two
control). One group (n = 10; 5 male, 5 female) of rats
was weaned onto an ad lib liquid ethanol-containing
diet for 3 weeks. Rats began the ethanol (ET) diet at
2.2% v/v and were gradually weaned up to 4.5% v/v and
finally 6.7% v/v. After this initial exposure, rats received
6.7% v/v liquid ethanol diet for three consecutive days
each week, followed by 4 days of ad lib solid rat chow
pellets (Purina). A second group of rats (n = 10) was
paired with the ET-fed rats based on gender and initial
body weight (pair-fed control rats), and received aliquots
of a liquid control diet defined by the amount of food
consumed by the paired ET-fed rats.
The liquid diet was obtained from OpenSource Re-
search Diets™. Maltose replaced ethanol in the control
pair-fed (PF) diet to match for caloric and nutritional
content. Throughout the study duration, regular records
of the rats’ body weights and ethanol (or control diet)
consumption were maintained. At the end of the study,
all rats in each group were euthanized with CO2 and
samples of their cardiac blood were obtained for RNA
isolation into PaxGene RNA stablization solution or
serum separator tubes for liver enzyme testing (AST,
ALT, ALP, total protein). Rats were then transcardially
perfused with approximately 30 mL Phosphate Buffered
Saline (PBS) followed by 30 mL RNAlaterW (Qiagen)
which was used to stabilize RNA in the brain tissues and
was not collected. RNA was extracted according to
standard PaxGene protocols and differential expression
of transcripts was investigated using a Rat Gene 1.0 ST
Array (Affymetrix),
RMA-normalized data from the rat and previously-
published mouse microarrays were analyzed using Partek
Genomic Suite to identify common patterns of expres-
sion level changes in a set of 350 genes of interest
involved in cell proliferation, apoptosis, DNA-repair, and
p53-signaling pathways according to the SA Biosciences
database. A pairwise two-way analysis of variance
(ANOVA) was used to identify genes altered significantly
by alcohol in the rats for comparison with the mouse
NS-5 data on the same genes. The mouse and rat data
for these genes were then compared using Pearson cor-
relation. Significance for this was based on a step-up
multiple testing correction, with the false discovery rate
(FDR) set at 0.1. Thirty-four of these genes were selected
for validation in rats (and humans) using a QuantiGene
Plex 2.0 (QGP) assay (Affymetrix), as described below.
The complete set of genes included in the QGP assay is
displayed in Table 1.Human studies
Recruitment and inclusion/exclusion criteria
All procedures were approved by the Institutional Re-
view Board (IRB) of SUNY Upstate Medical University
as well as Crouse Irving Memorial Hospital. A total of
65 subjects participated in this study. This included 50
subjects with a current diagnosis of an alcohol use
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The AUD subjects included 40 with alcohol dependence
(AD) and 10 with alcohol abuse (AA), according to
DSM-IV criteria. Subjects were recruited from the
greater Syracuse area, the Crouse Irving Memorial Hos-
pital Chemical Dependence Treatment Services Clinic,
Syracuse Behavioral Health, Tully Hill Chemical De-
pendency Treatment Center, ARISE Child and Family
Services, and Syracuse University.
Exclusion criteria included age less than 18 years, or
greater than 60 years, weight greater than 270 lbs., preg-
nancy, co-morbid drug abuse (except for cigarette smok-
ing), history of head injury with loss of consciousness or
co-morbid medical conditions including diabetes, cancer,
hepatitis C, neurological diseases (e.g. seizure disorder)
and major mental illness (except for anxiety disorders
and major depression). In addition patients with metallic
implants of any kind (braces, pacemakers, etc.) or claus-
trophobia were excluded based upon MRI incompatibil-
ity. The Structured Clinical Interview (SCID) for the
Diagnostic and Statistical Manual of the American Psy-
chiatric Association, 4th edition (DSM-IV) was adminis-
tered to all subjects by a psychiatrist to establish a
definitive diagnosis of alcohol dependence or abuse. As a
supplement to the SCID, the Semi-Structured Assess-
ment for the Genetics of Alcoholism Version IV
(SSAGA-IV) was administered to obtain participant
demographics, past medical history, and tobacco and al-
cohol use in a format that could be easily cross-
referenced to other studies.
Medical, demographic, and neuropsychological assessments
After obtaining informed consent, subjects were initially
screened for drugs of abuse using a dipstick urine toxi-
cology screen and breath alcohol test. Over the course
of two subsequent appointments, subjects completed a
blood draw, brief neurological exam, neuropsychological
testing, and a structural brain MRI. A total of three
blood tubes were collected from each subject: one for
RNA isolation (PaxGene) from leukocytes in the venous
blood, a second for complete blood cell count and differ-
ential white blood cell count and the third for routine la-
boratory measures that determined basic metabolic
status, including blood glucose, and serum levels of AST,
ALT, and GGT to reveal liver damage. The total RNA
was extracted from the samples of venous blood accord-
ing to PaxGene protocol and processed by the SUNY
Microarray Core facility (SUNYMAC) to determine the
expression level of a set of 34 genes using a custom-
designed Quantigene Plex 2.0 assay (Affymetrix), as
described below.
The neurological examination screened for obvious
signs of cerebellar damage (ataxia, dysmetria, decompos-
ition of movement, dysdiadochokinesia, and smoothpursuit eye movement impairments). Neuropsycho-
logical tests included the Wechsler Abbreviated Scale of
Intelligence (WASI), the Wechsler Memory Scale
(WMS) and selected scales from the Delis-Kaplan Ex-
ecutive Function System (DKEFS), including the trail-
making tasks and verbal fluency tasks. These tests were
chosen based upon their extensive use in clinical prac-
tice for assessment of cognition.
The structural brain MRI series was obtained from all
human subjects in the sagittal plane on a 1.5 T Philips
Gyroscan scanner from Philips Medical Systems™. Each
scan utilized the following T-1 weighted inversion recov-
ery 3-D pulse sequence: TE = 4.6; TR = 20; 2 repetitions,
matrix size 256 X 154; FOV 24; multishot = 32; TFE pre
IT shortest (394 ms), 1.5 mm slice thickness. Analysis of
the images was performed to determine the extent of
CNS damage (if any) in AUD subjects compared to non-
drinking controls. Images were evaluated for evidence of
gross structural abnormalities by a trained neuroanatom-
ist and any unusual findings were followed up with a
neuroradiologist. The analysis that was performed uti-
lized a semi-automated image reconstruction and seg-
mentation software suite (FreeSurfer) developed by the
Martinos Center (Harvard/MGH). This software gener-
ated parcellated volumes for more than 360 cortical and
subcortical brain structures, including cortical gray mat-
ter, white matter, gyri and sulci.
Analysis of the combined medical, demographic,
neuropsychological and neuroimaging data was per-
formed to identify significant group differences between
AUD and control subjects. A total of 423 variables were
tested, with Benjamini-Hochberg FDR-corrected signifi-
cance set at 0.1. Significant variables from this analysis
were combined with significantly affected genes identi-
fied in the QuantiGene Plex 2.0 analysis (described
below) and subjected to correlation analysis and princi-
pal components analysis (PCA). Genes were selected
for correlation and PCA analysis if they displayed nom-
inally significant changes in the QuantiGene Plex assay
(p ≤ 0.05) as well as nominally-significant changes in ei-
ther human lymphoblasts exposed to ethanol, mouse
NS-5 cells exposed to ethanol, or PBLs from binge-
drinking adolescent rats. For the correlation analysis in
human subjects, we used Pearson r values, with r to t
transformation used to determine nominal p values,
which were then adjusted using a Bonferroni correction
(based on examination of 3039 unique correlation tests).
For the PCA analysis, we focused on the factors that
described 75% of the variance of the significantly chan-
ged variables and performed hierarchical clustering on
the oblique factor weights. Genes of interest identified in
this approach were subsequently examined for signifi-
cant differences between AA, AD and Control subjects
using a one-way analysis of variance (ANOVA) with a
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for post-hoc comparisons.
Lymphoblast assays
To complement the human, rat and mouse studies, we
also examined cultured lymphoblasts (LBs) for ethanol-
induced changes in gene expression. Cells for these stud-
ies were obtained from an immortalized LB cell line that
had been derived from Epstein-Barr Virus transformed
B lymphocytes of a healthy non-alcoholic control sub-
ject. Frozen stocks of these cells were thawed and ini-
tially grown in RPMI 1640 Complete media in T-75
flasks, with 10% heat-inactivated fetal bovine serum,
penicillin-streptomycin (100 U), gentamicin (100 ug/ml),
L-glutamine (2 mM), and HEPES (10 mM). Cells were
split after reaching approximately 75% confluency.
Approximately 50,000 cells were then plated (in a 6.5 ml
volume) into 4 replicate wells of a 6 well plate that had
been coated with laminin (10 ug/ml; Sigma) for treat-
ment with either ethanol (200 mg/dL) or control media.
The concentration of ethanol in the media was mea-
sured at regular intervals throughout each exposure
using a GM-7 Microstat (Analox Instruments). At the
end of the treatments, RNA was isolated from each well
and used for quantification of gene expression using the
QuantiGene Plex 2.0 Assay, as described below.
QuantiGene plex 2.0 Assays
Rat and human total RNA samples were processed
according to the Affymetrix QuantiGene Plex 2.0 Assay
Manual. Briefly, a working bead mix was prepared con-
taining lysis mixture, blocking reagent, capture beads,
and 2.0 probe set. The bead mix was dispensed into the
hybridization plate, and 20ul of total RNA was added to
each well. For background control wells, 20ul of sterile
nuclease-free water was added to the bead mix. The
hybridization plate was sealed with a pressure seal and
placed into a VorTemp 56 shaking incubator (Fisher).
The plate was incubated for 22 hours at 54 °C and
600RPM.
After hybridization, the wash solution, pre-amplifier,
amplifier, label probe, and streptavidin-phycoerythrin
(SAPE) solutions were prepared according to the manual
instructions. The hybridized samples were then trans-
ferred from the hybridization plate to the magnetic sep-
aration plate. Samples were washed using the Affymetrix
Hand-Held Magnetic Plate Washer, and incubated se-
quentially for 1 hour each (50 °C at 600RPM) with the
pre-made amplifier solutions (pre-amplifier, amplifier,
and label probe). The SAPE solution was then added to
the plate and samples were incubated at room
temperature for 30 minutes at 600RPM. The plate was
covered in foil to protect samples from light. The un-
bound SAPE was then washed away using the SAPEWash Buffer from the QuantiGene Plex Kit. Then, 130ul
of SAPE Wash Buffer was added to each sample, and the
plate was shaken at room temperature for 3 minutes at
800RPM to resuspend the beads. The plate was read im-
mediately using the BioRad BioPlex 200 instrument. The
settings on the BioPlex instrument were set to: sample
size 100ul; timeout 60 seconds; Bead Events/Bead region
100.
Fluorescent readings from blank wells were subtracted
from fluorescent values for each mRNA of interest.
These values were then normalized against the geomet-
ric mean expression of two control genes for each sam-
ple: cyclophilin A (PPIA) and hypoxanthine-guanine
phosphoribosyltransferase (HPRT1). Expression values
for each gene were multiplied by a constant and com-
pared between alcohol-exposed and non-exposed sam-
ples using a two-tailed t-test to identify those transcripts
significantly altered by alcohol (p < 0.05).
Results
In this study, we compared the effects of ethanol expos-
ure on expression of genes involved in p53 signaling, cell
proliferation, DNA repair and apoptosis in mouse NSCs
in vitro with the effects seen in circulating PBLs
obtained from binge drinking adolescent rats. The com-
bined results were used to examine changes in the same
set of genes in cultures of human lymphoblasts exposed
to ethanol in vitro and in PBLs obtained from human
subjects with AUD. The expression data for the most ro-
bustly affected genes in human AUD subjects were also
examined for possible associations to various demo-
graphic, medical, neuropsychological, and neuroimaging
variables.
Rat drinking data, estimated blood ethanol
concentrations, and liver enzymes
All of the binge-drinking and pair-fed control rats
gained weight normally through the 3 week time course
of the study. Males tended to gain significantly more
weight than females (increase = +121% vs +86% of their
starting body weight, p < 0.01). The weight gain experi-
enced by the binge drinking rats was not significantly
different from their pair-fed controls (increase = +98% vs
+108% of their starting body weight, p = 0.07). Binge
drinking rats consumed an average of 278.4 ml of 6.7%
ethanol-containing liquid diet per Kg of body weight.
The amounts consumed by males and females did not
differ significantly (p > 0.12). Because the rats included
in this study were engaged in binge-drinking, but had
not received ethanol on the morning of their euthanasia,
it was not possible to directly obtain accurate estimates
of their binge state blood ethanol concentrations (BECs).
Nonetheless, based on our past experience with the
same strain and ages of rats being fed the identical 6.7%
Table 2 40 genes significantly changed in mouse NS-5
cells and rat PBLs
Log2 Changes Confirmed Change?
Gene Mouse NS-5 Rat PBL Mouse NS-5 Rat PBL
Api5 -0.11 0.96
Bnip3 0.56 -0.29
Bub1 -1.56 -0.63 X
Card6 -0.76 0.49 X
Casp14 -0.19 -0.37
Ccnb2 -4.12 -0.60 X X
Ccnf -2.90 -0.65 X
Cdc20 -3.32 -0.98 X
Cdc6 -2.55 -0.49
Cdca5 -2.89 -0.31 X
Cdca8 -3.10 -0.56



















Pttg1 -2.99 -0.92 X X









These genes were significantly changed by microarray in both mouse NSCs
and rat PBLs.
X’s indicate those genes which were independently confirmed using either
real-time qRT-PCR (mouse) in the Hicks et al. reports [15,16] or QuantiGene
Plex (rat) in the current study.
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mate the approximate peak BECs in our rats based on
their age, weight, and daily consumption data using
the formula BEC = 0.5 × [Amount consumed per body
weight (in ml/Kg)] + 6.76. According to this formula,
estimated peak BECs for our rats equaled approximately
145 mg/dl. The estimated values did not differ signifi-
cantly in the males and females (139.0 vs 150.3,
p = 0.125). These values are within the ranges seen in
previous studies of adolescent rats fed liquid ethanol
diet, and are significantly greater than the 80 mg/dl
(0.08%) BECs typically achieved in human binge drinkers
who have consumed more than 4 or 5 drinks in a two-
hour period (NIAAA.nih.gov).
Data from the liver enzyme panel indicated no changes
in serum aspartate aminotransferase (AST) or total pro-
tein levels in binge-drinking rats compared with pair-fed
controls. However, significant elevations were see in ala-
nine aminotransferase (ALT) levels (66.1 U/L vs 46.4
U/L, p < 0.03) and alkaline phosphatase (ALP) levels
(379.6 U/L vs 306.9 U/L, p < 0.005). Both ALT and ALP
are sensitive indicators of liver damage. Combined with
the estimated BEC values, these data support the notion
that the binge drinking paradigm was effectively model-
ing some aspects of human alcohol abuse.
Mouse and rat array data comparisons
Our previous microarray analysis of NS-5 cells exposed
to ethanol under two different growth factor conditions
indicated that 74 out of 350 unique genes involved in
p53 signaling, cell proliferation, DNA repair and apop-
tosis showed significant changes in expression [15]. Of
these 74 genes, 14 have been validated (independently
confirmed) by qPCR analysis [15,16].
In the present study, using PBLs from a rat adolescent
binge drinking model, we found even more striking
effects in this set of pathways, with 190 out of 350
unique genes showing significant expression changes
after correction for multiple testing. A total of 40 unique
genes were significantly affected in both the mouse
NSCs and rat PBL studies (Table 2). A direct compari-
son of the magnitude and direction of expression
changes in the two experiments was performed using
both correlation analysis and hierarchical clustering.
These comparisons revealed that overall the changes
observed for the 40 overlapping genes were significantly
correlated, particularly for genes with decreased expres-
sion in mouse NSCs (Figure 1). Moreover, we also
observed very little influence of growth factor conditions
in vitro (FGF, TGF) or gender on the magnitude and dir-
ection of expression change for these genes (Figure 2).
Most of the genes with consistently decreased expres-
sion were involved in mitotic cell cycle regulation (e.g.,






















Log 2 Change Mouse
Figure 1 Comparison of ethanol-induced significant expression
changes in cell proliferation, DNA repair, and apoptosis genes
seen in mouse NSCs and rat PBLs. Note that overall, the
expression level changes were significantly correlated, particularly for
genes with decreased expression in mouse NSCs. Data for the NS-5
comparisons obtained from Hicks et al. study [15].
Figure 2 Hierarchical cluster analysis of ethanol-induced changes in e
and apoptosis genes seen in mouse NSCs (columns 1-4) and rat PBLs
growth factor conditions in vitro (FGF, TGF) or to gender. Also note that m
expression and involved in mitotic cell cycle regulation (e.g., cyclin B2, pitu
repair and apoptosis tended to show increases in expression, although the
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tended to show increases in expression, although the
changes varied somewhat by cell type.
Based on the correlated changes in the microarray
data for the mouse and rat samples, we designed a cus-
tom QuantiGene Plex 2.0 assay to enable us to inde-
pendent confirm the gene expression changes in the rat
and determine whether changes in the same class of
genes occur in human PBLs from AUD subjects or
human lymphoblasts exposed to ethanol. Approximately
half (14) of the genes in the custom assay had been pre-
viously observed to change in the mouse NSC studies,
while 19 were observed to change in the present rat PBL
study. A total of 9/19 of these rat PBL genes were
independently confirmed to be significantly (nominal
p < 0.05) changed in the same direction seen by micro-
array in the QuantiGene Plex 2.0 assay (Apaf1, Apex1,
Atm, Ccnb2, Cdc2/Cdk1, Gadd45a, Myc, Pttg1, andxpression of 40 genes involved in cell proliferation, DNA repair,
(columns 5-12). Note that very few differences were noted due to
ost of the genes in the top of the cluster diagram are decreased in
itary tumor-transforming gene 1). In contrast, genes involved in DNA
changes varied by cell type.
Hicks et al. BMC Neuroscience 2012, 13:128 Page 8 of 13
http://www.biomedcentral.com/1471-2202/13/128Racgap1). Of these 9 genes, 4 were also significantly
changed in the mouse NSC array data (Ccnb2, Cdk1,
Pttg1, and Racgap1; Table 2).
Human lymphoblasts
Of the 34 genes examined for expression changes in the
human lymphoblasts by the QuantiGene Plex assay, we
observed nominally significant changes in a total of 7,
according to parametric or non-parametric tests (Tp73,
Hus1, Gad45a, Atm, Pttg1, Mutyh, Cd40; Table 1). All 7
of these genes were decreased in expression, and one
(Pttg1) overlapped with the independently confirmed
changes seen in the mouse NSCs and rat PBLs (Table 2).
Human studies
Demographic and medical findings
There were no significant differences between our sub-
ject groups based on age or gender composition
(Table 3). AUD subjects, however, did show significantly
reduced gross personal income and years of education,
in addition to increased systolic blood pressure
(Table 4).
Neuropsychological findings
Compared with controls, AUD subjects demonstrated a
trend for decreased scores on auditory and visual mem-
ory, verbal and performance IQ, and verbal and
performance-based measures of executive function
(Table 4). Notably, however, the AUD subjects were not
different from the mean population normative values for
these standardized testing measures. Rather, the non-
drinking controls tended to display above average mem-
ory, IQ and executive function.
Neuroimaging findings
Of the more than 360 cortical and subcortical brain
structures that were examined for potential differences
between AUD and control subjects, we observed signifi-
cant differences in only 8 after correcting for multipleTable 3 Demographic and drinking variables of human subje
AUD (n = 50)
Gender (Females, Males) 18 F, 32 M
Age (years) 38.2
Drinking Days Last Month 18.5
Standardized Drinks Last Week 27.1
Drinking Days Last Week 3.6
Drinks/Drinking Day 6.6
Heavy Drinking Days Last Week 2.2
Age at Onset of Drinking Disorder 19.5
Years Drinking 18.5
AA, alcohol abuse; AD, alcohol dependence, AUD, alcohol use disorder; F, female; Mtesting (Table 4). These 8 areas comprise 4 distinct brain
regions: (1) the left frontal operculum (including Broca’s
area 45, inferior triangular gyrus, and pars triangularis);
(2) the right frontal operculum (including pars opercu-
laris and frontal inferior opercular gyrus); (3) the right
superior temporal area (including the temporal superio-
lateral gyrus and superiortemporal cortex); and (4) the
left parietal inferior supramarginal gyrus (Table 4). All of
these brain regions showed significant volume reduc-
tions in AUD subjects relative to non-drinking controls,
ranging from 1.13 fold to 1.21 fold.
Genes
Of the 34 genes examined for expression changes in the
human PBLs, we observed nominally significant changes
in a total of 7 (Hus1, Tp53, Myc, Mutyh, Cdk4, Cdk4,
Ercc1, and Mcm5; Table 4). All 7 of these genes were
decreased in expression in human AUD subjects, and 2
(Hus1, Mutyh) overlapped with the genes significantly
decreased in the human lymphoblasts. None of the
remaining genes overlapped with the genes independ-
ently confirmed as changed in the rat QuantiGene Plex
assays.
Principal components factor analysis
We constructed a correlation matrix for the 40 demo-
graphic, medical, neuropsychological, neuroimaging, and
gene expression variables that distinguished our AUD
and control subjects, followed by a PCA and hierarchical
clustering of the loadings for the first 8 factors (which
accounted for 75% of the variance in the significantly
changed variables). These analyses revealed clear asso-
ciations in the data for effects on neuropsychological
variables (heaviest loading on factor 1), mRNA (heaviest
load on factor 2), drinking variables (heaviest load on
factor 3), and neuroimaging variables (heaviest load on
factors 4 and 5). One exception to this general trend
concerned the left hemisphere parietal inferior supra-
marginal gyrus, which showed a stronger relationship tocts
AD (n = 40) AA (n = 10) Controls (n = 15)










Table 4 Variables significantly different between AUD and control subjects
Variable AUD ave Control ave Fold Change Nominal P BH FDR
Medical/Demographic
Income 2.4 5.1 -2.16 0.00003 0.013
Years Education 13.2 15.7 -1.19 0.00007 0.015
Blood Pressure (Systolic) 135.2 118.9 1.137 0.00364 0.070
Neuropsychological
Full Scale IQ Percentile 53.3 83.6 -1.57 0.00024 0.025
Full Scale IQ 101.3 118.0 -1.16 0.00025 0.018
Verbal IQ 100.8 116.9 -1.16 0.00038 0.023
Verbal IQ Percentile 52.3 81.6 -1.56 0.00045 0.021
Combined Number-Sequencing Letter-Sequencing Score 10.0 13.1 -1.30 0.00058 0.025
Performance IQ 101.4 115.7 -1.14 0.00108 0.042
Performance IQ Percentile 53.6 80.5 -1.50 0.00115 0.041
General Memory Percentile 51.8 80.0 -1.55 0.00146 0.048
Auditory Immediate Memory Percentile 47.2 76.2 -1.61 0.00151 0.046
Number Sequencing Score 9.2 12.1 -1.32 0.00176 0.046
Visual Delayed Memory Percentile 49.4 73.9 -1.49 0.00249 0.062
Auditory Delayed Memory Percentile 51.0 77.2 -1.51 0.00335 0.079
Letter Fluency Score 10.0 12.9 -1.29 0.00416 0.076
Category Fluency Score 10.9 13.7 -1.26 0.00499 0.088
Letter Sequencing Score 9.8 12.3 -1.25 0.00517 0.087
Neuroimaging
Right Hemisphere Temporal Superiolateral Gyrus 4674.4 5642.7 -1.21 0.00009 0.013
Left Hemisphere Broca’s Area 45 6164.8 7197.7 -1.17 0.00025 0.021
Left Hemisphere Frontal Inferior Triangular Gyrus 2640.2 3232.1 -1.22 0.00042 0.022
Right Hemisphere Pars Opercularis 3956.7 4676.1 -1.18 0.00168 0.047
Right Hemisphere Superiortemporal 11098.8 12513.5 -1.13 0.00336 0.075
Left Hemisphere Parietal Inferior Supramarginal Gyrus 6301.8 7368.1 -1.17 0.00350 0.074
Left Hemisphere Pars Triangularis 3537.5 4218.3 -1.19 0.00351 0.071
Right Hemisphere Frontal Inferior Opercular Gyrus 3034.4 3493.7 -1.15 0.00540 0.088
Genes
HUS1 checkpoint homolog (S. pombe) 493.7 558.3 -1.13 0.05221 -
TP53 tumor protein p53 142.7 217.5 -1.52 0.01665 -
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 216.0 312.4 -1.45 0.01402 -
MUTYH mutY homolog (E. coli) 54.5 68.0 -1.25 0.02417 -
CDK4 cyclin-dependent kinase 4 389.8 446.3 -1.14 0.02410 -
ERCC1 excision repair cross-complementing
rodent repair deficiency, complementation group 1
627.9 735.3 -1.17 0.03782 -
MCM5 minichromosome maintenance complex component 5 307.5 396.8 -1.29 0.02045 -
Variables are grouped by category. Benjamini-Hochberg False Discovery Rate (BH FDR) was used to correct P values, except for gene data, where nominal P values
are listed.
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most heavily on factor 2 than to factors 4 and 5, that
best accounted for the variance of other neuroimaging
measures (Figure 3).
To further probe the PCA results specifically in
regards to the gene expression results, we examined the
Bonferroni-corrected correlation matrix and identifiedtwo striking findings. First, all 7 of the significantly
changed genes showed robust positive correlations with
each other, almost all of which survived Bonferroni cor-
rection (not shown). Secondly, the expression of both
Ercc1 and Mcm5 showed highly significant correlations
with the volume of the left hemisphere parietal inferior
supramarginal gyrus (Figure 4). This relationship was
Figure 3 Hierarchical cluster analysis of the factor loading scores from 40 demographic, medical, neuropsychological, neuroimaging,
and gene expression variables that distinguish subjects with alcohol use disorders from healthy controls. Note the trends for significantly
changed neuropsychological variables to load most heavily on factor 1, significantly changed genes to load on factor 2, drinking variables to load
on factor 3, and neuroimaging variables to load on factors 4 and 5. One exception to this is the left hemisphere parietal inferior supramarginal






































































Figure 4 Highly significant correlations between Ercc1 (left) or Mcm5 (right) expression in human PBLs and the volume of the left
parietal inferior supramarginal gyrus. The histogram plots (inset) show the results of an ANOVA comparing the expression levels of Ercc1 and
Mcm5 in all three subject groups. Note that both genes showed a significant main effect of diagnosis, but there was a clear trend for alcohol
dependent (AD) subjects to show more of a decrease in expression compared to controls (Ctrls) than alcohol abusing (AA) subjects.
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http://www.biomedcentral.com/1471-2202/13/128suggested by the close clustering of these variables in
the PCA matrix (Figure 3). Further examination of the
expression levels of these genes using a one way
ANOVA indicated significant differences across the 3
diagnostic groups (AA, AD and Controls) with a clear
trend for AA subjects to show only modest decreases
(which were not significant) while AD subjects showed
significant decreases relative to controls (Figure 4, inset
graphs).
Three other groups of nominally-significant correlations
were also noted for Ercc1 and Mcm5, including: (1) posi-
tive correlations with multiple brain region volumes, in-
cluding the right hemisphere equivalent of the left
parietal inferior supramarginal gyrus (r = 0.54), the left
and right middle temporal lobes (r = 0.33 to 0.44), the left
and right caudate nucleus and thalamus (r = 0.30 to 0.47),
and total left and right cortical gray matter (r = 0.37 to
0.41). (2) positive correlations (r = 0.25 to 0.39) with 13 of
the 15 significantly changed neuropsychological variables
listed in Table 4 (the only exceptions being the Number
Sequencing Score and Visual Delayed Memory Percent-
ile); and (3) positive correlations between Ercc1 and abso-
lute eosinophil and basophil counts along with a modest
negative correlation between Ercc1 levels and absolute
lymphocyte counts (r = -0.30).
Discussion
The effects of alcohol use disorders exert a tremendous
impact on the central nervous system of adult humans
[1,2,17]. Alcohol exposure affects the normal processes
of neuronal proliferation, repair, and apoptosis in
humans [10,18] and in animal models [19,20]. The p53-
signaling pathway regulates each of these processes [21]
and has been implicated in ethanol-induced changes in
the central nervous system [15,22]. The current study
focuses on examination of the expression of p53-related
genes in human and rat PBLs and identifies sets of
ethanol-responsive genes that are correlated with
changes in brain structure and function.
One of our major findings is that the expression of the
p53 gene and six p53-related genes are decreased in the
blood of human subjects with AUD. Furthermore the
expression levels of several of these genes (particularly
Ercc1, Mcm5, and p53) are positively correlated with the
volumes of several cortical and subcortical brain regions,
(particularly the left parietal supramarginal gyrus) as well
as several measures of significantly affected neuro-
psychological variables. When combined with our results
from the mouse NSCs and rat PBLs, this suggests that
alterations in p53 signaling may be occurring within the
brain of subjects with AUD. Support for this possibility
comes from studies of rat pups exposed to ethanol,
which demonstrated reduced p53 expression in the
developing cortex [22], as well as gene expressionstudies of postmortem human brain. Specifically, one
study of the frontal cortex of adult human alcoholics
identified changes in 35 neurogenesis-related transcripts
and 11 apoptosis-related transcripts – both of which are
highly regulated by p53 [9].
Our findings regarding Ercc1 levels are particularly
noteworthy for several reasons. The Ercc1 gene-product
is involved in nucleotide excision repair (NER) of
damaged DNA [23]. This process is potentially highly
relevant to understanding the effects of ethanol on gen-
omic integrity. For example, the process of NER is a crit-
ical means for removing harmful DNA adducts that can
form after exposure to ethanol or its metabolites. In-
deed, in cancer therapy, NER is viewed as the primary
mechanism whereby platinum-DNA adducts are
removed from the DNA of tumor cells following cis-
platin treatment. Accordingly, Ercc1 activity levels have
been viewed as a potentially important prognostic bio-
marker for tumor responsiveness to cisplastin [24,25]. In
AUD subjects Ercc1 expression was nominally correlated
with the age of onset of the alcohol use disorder and ro-
bustly and significantly correlated with the volume of
the supramarginal gyrus in the left inferior parietal lobe
region. Thus, the importance of Ercc1 in repairing
ethanol-associated DNA damage may increase over the
lifespan - particularly for this brain region, which is now
well-established as involved in several aspects of lan-
guage processing (e.g., [26]). Several recent studies lend
even stronger support for this notion. For example, the
Ercc1 null mouse has been used as a model of acceler-
ated aging (progeria) because it exhibits shunted growth,
wasting, ataxia, and premature death by 1-2 months of
age [27,28]. Mice with reduced expression of Ercc1, how-
ever, show a less rapid progeria phenotype, surviving
until 4-6 months of age, but exhibit clear signs of meta-
bolic, neurologic, and cognitive decline (including learn-
ing and memory deficits) along with neurodegenerative
changes (elevated expression of markers that indicate re-
active astrocytosis and apoptosis) [29,30]. A recent fol-
low up study of these mice by Vegh and colleagues [31]
revealed that even before these types of changes are seen
in the hippocampus, there are significant reductions in
the expression levels of numerous proteins involved in
synaptic function during the early stages of accelerated
aging due to reductions in Ercc1 expression, which they
proposed were the cause of the learning and memory
deficits in these mice. Thus, DNA damage repair pro-
cesses may be critical for preventing age-dependent cog-
nitive decline in otherwise normal mice. Given that our
AUD subjects showed significantly reduced Ercc1 ex-
pression and performance on several standardized mea-
sures of verbal function, the present study strongly
suggests a role for DNA repair processes and Ercc1 in
preventing alcohol-dependent cognitive decline as well.
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Ercc1 expression, brain volume, neuropsychological
function, aging, and cancer risk merits further investiga-
tion. In addition, there may be other explanations for
the changes in Ercc1 levels that we have not considered.
Our findings regarding Mcm5 are also highly novel
and may relate to the Ercc1 findings in terms of the rela-
tionship with the volume of the left inferior parietal
supramarginal gyrus. The Mcm5 gene product is a
chromatin-binding protein that regulates the initiation
of the cell cycle at the G0-G1/S transition [32] and is
negatively regulated by p53 [33]. Not only is MCM5
down-regulated in human PBLs, it is also down-
regulated in the frontal cortex of human alcoholics [8,9]
and in mouse neural stem cells exposed to ethanol
(11-fold decrease; 15). Such changes could lead to a re-
duction in cell proliferation. If such effects are also
present in the brain of subjects exposed to ethanol dur-
ing sensitive developmental periods, this could help ex-
plain why alcohol-induced decreases in Mcm5 are
correlated with reductions in the volumes of several
brain regions, such as the left inferior parietal supramar-
ginal gyrus of AUD subjects.
Together, the Tp53, Ercc1, and Mcm5 genes represent
intertwined pathways altered by ethanol exposure.
Alcohol-induced down-regulation of Mcm5 and other
cell cycle-related transcripts (Myc, Cdk4, Pttg1) may lead
to checkpoint restriction at both G0 and G2/M. This
interruption of proliferation is necessary for activation of
DNA-repair mechanisms (i.e. Hus1, Mutyh, Ercc1) sec-
ondary to alcohol-induced oxidative stress [34]. The
master regulator of these processes is Tp53, a gene that
controls cell fate through the orchestration of repair and
proliferation and the initiation of apoptosis [35]. We can
now confirm that the p53-pathway is affected by alcohol
in both the CNS and peripheral blood of humans and
animal models. Moreover, this study has identified spe-
cific players within the p53-pathway that serve as bio-
markers for the deleterious effects of alcohol. These
genes are not only correlated with changes in brain vol-
ume and function, but may also play an integral role in
the pathophysiology of alcohol-induced CNS damage.
There are a number of notable limitations to the
present study that should be mentioned. First, we did
not measure the expression of genes in the brains of
AUD subjects since this was not a postmortem study.
Nonetheless, our results on p53-related genes are con-
sistent with results from prior postmortem studies. Sec-
ond, the significant changes seen in the rat and human
PBLs appeared to be largely distinct, although both sets
of data clearly supported our hypothesis that p53-related
genes would be affected, and there was significant asso-
ciation between the rat PBL results and mouse NSC
results. Third, we did not assess brain volumes or brainfunction in the rat drinking model, and thus far we have
only established the relationship between changes in
p53-related genes in a single drinking paradigm. Finally,
it is possible that some of the differences we are ascrib-
ing to ethanol that were found between AUD and con-
trol subjects may be influenced by the fact that our
controls appeared to be very high functioning relative to
the general population on several neuropsychological
measures. Although this potential bias may be difficult
to avoid when selecting non-drinking subjects for inclu-
sion in this type of study, it also argues in favor of add-
itional studies.
Conclusion
We have identified a specific set of p53-related genes
that are altered by ethanol exposure in both humans and
animal models in proliferating cells of the CNS and
blood. Though the expression changes of these genes are
important in understanding the mechanisms underlying
ethanol-induced CNS damage, their expression level
changes in peripheral blood are perhaps equally import-
ant as biomarkers of CNS damage. For example, the ex-
pression of Mcm5 and Ercc1 are correlated with
increased alcohol consumption and decreased volume of
the thalamus and caudate bilaterally. Similarly, Mcm5
and Ercc1 demonstrate robust correlations with category
fluency and verbal IQ, respectively. Because Mcm5 and
Ercc1 are strongly correlated with a cluster of p53-
related transcripts this entire group of genes may hold
clinical value as biomarkers of CNS damage and func-
tional impairment in patients with AUD.
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Additional file 1: Figure S1. Experimental overview. The rationale for
the present study was based on our recently published findings [15,16]
regarding the in vitro effects of ethanol on mRNA expression in mouse
neural stem cells (NSCs), where changes in a considerable portion of
genes involved in p53 signaling, cell cycle regulation, apoptosis and DNA
damage and repair were observed and independently confirmed using
real-time quantitative RT-PCR (qRT-PCR). In the present study, we first
examined whether there were similar changes in peripheral blood
leukocytes (PBLs) in an in vivo rat binge drinking model using microarray
data. Then, based on the considerable overlap and correlated changes,
we confirmed several of the rat findings and tested their validity in two
sets of human samples: PBLs from subjects with alcohol use disorders,
and lymphoblasts (LBs) from a normal human subject. We noted that all
four of these data sources showed evidence of dysregulation of the
genes of interest, although the specific genes most affected could vary
across models. In addition, several of the genes showed highly significant
correlations with medical, neuropsychological, neuroimaging, and
demographic traits in our human subjects.
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